Absci Corporation (Nasdaq: ABSI), a pioneer in generative AI drug creation, has announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK), a globally recognized leader in cancer treatment and research. The partnership aims to leverage Absci's Integrated Drug Creation™ platform and MSK’s expertise to discover and develop new therapeutics across up to six programs.

The collaboration underscores the potential of combining cutting-edge AI technology with leading oncology research to drive innovation in cancer treatment. “MSK has an incredible record of groundbreaking translational and clinical innovations in oncology,” said Sean McClain, Founder & CEO of Absci. “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.”

“At MSK, we are committed to continuous innovation as we strive toward our mission of ending cancer for life, and we expect cancer care AI to play an increasingly important role,” said Gregory Raskin, MD, Senior Vice President of Technology Development at MSK. “We look forward to collaborating with Absci in leveraging the company’s generative AI platform in our ongoing efforts to advance cancer research and develop new therapies for our patients.”

This partnership with MSK adds to Absci’s growing portfolio of collaborations focused on developing novel biologics for challenging diseases. Over the past year, Absci has teamed up with global pharmaceutical leaders and research institutions, including AstraZeneca and Almirall, alongside ongoing partnerships with Merck, NVIDIA, and others. Beyond these collaborations, Absci continues to advance its internal drug pipeline, including ABS-101, a potential best-in-class anti-TL1A antibody, which has been designed and optimized using its generative AI platform.

The collaboration between Absci and MSK represents a significant step forward in the integration of AI and oncology, with the potential to accelerate the development of breakthrough therapies for cancer patients.

‍